Hu M, Meng X, Wang T, Wang Y, Chen X, Xu D
J Cancer Res Clin Oncol. 2025; 151(1):38.
PMID: 39825073
PMC: 11741992.
DOI: 10.1007/s00432-025-06087-z.
Liu C, Gao J, Cheng Y, Zhang S, Fu C
Regen Biomater. 2025; 12:rbae135.
PMID: 39811105
PMC: 11729729.
DOI: 10.1093/rb/rbae135.
Li A, Qi F, Zeng Y, Liu R, Cai H, He M
Adv Sci (Weinh). 2025; 12(9):e2414307.
PMID: 39804941
PMC: 11884613.
DOI: 10.1002/advs.202414307.
Li K, Guo B, Gu J, Ta N, Gu J, Yu H
Mater Today Bio. 2025; 30:101375.
PMID: 39759851
PMC: 11699619.
DOI: 10.1016/j.mtbio.2024.101375.
Lu E, Zhou K, Miao J, Zhu Y, Tang J, Du S
J Nanobiotechnology. 2025; 23(1):8.
PMID: 39757205
PMC: 11702283.
DOI: 10.1186/s12951-024-03018-x.
Autophagosomes coated in situ with nanodots act as personalized cancer vaccines.
Huang W, You W, Zhu Y, Gao F, Wu Z, Chen G
Nat Nanotechnol. 2025; .
PMID: 39753731
DOI: 10.1038/s41565-024-01826-8.
Tailoring cell-inspired biomaterials to fuel cancer therapy.
Wang Q, Cheng S, Han C, Yang S, Gao S, Yin W
Mater Today Bio. 2025; 30:101381.
PMID: 39742146
PMC: 11683242.
DOI: 10.1016/j.mtbio.2024.101381.
Nanotechnology Advances in the Detection and Treatment of Lymphoid Malignancies.
Adamo F, De Falco F, Dorillo E, Sorcini D, Stella A, Esposito A
Int J Mol Sci. 2024; 25(17).
PMID: 39273202
PMC: 11395233.
DOI: 10.3390/ijms25179253.
A Multi-Functional Nanoadjuvant Coupling Manganese with Toll-Like 9 Agonist Stimulates Potent Innate and Adaptive Anti-Tumor Immunity.
Liu Z, Li S, Xiao Y, Liu X, Zhang B, Zeng Q
Adv Sci (Weinh). 2024; 11(41):e2402678.
PMID: 39258810
PMC: 11538688.
DOI: 10.1002/advs.202402678.
Biomimetic Nucleic Acid Drug Delivery Systems for Relieving Tumor Immunosuppressive Microenvironment.
Yan W, Cao Y, Yin Q, Li Y
Pharmaceutics. 2024; 16(8).
PMID: 39204373
PMC: 11360391.
DOI: 10.3390/pharmaceutics16081028.
Freezing biological organisms for biomedical applications.
Kuang G, Zhang Q, Jia J, Yu Y
Smart Med. 2024; 1(1):e20220034.
PMID: 39188743
PMC: 11235656.
DOI: 10.1002/SMMD.20220034.
Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the "Smart" exosome nanoparticle therapy.
Wu X, Ban C, Deng W, Bao X, Tang N, Wu Y
Mol Cancer. 2024; 23(1):144.
PMID: 39004737
PMC: 11247735.
DOI: 10.1186/s12943-024-02057-0.
Hematopoietic stem and progenitor cell membrane-coated vesicles for bone marrow-targeted leukaemia drug delivery.
Li J, Wu H, Yu Z, Wang Q, Zeng X, Qian W
Nat Commun. 2024; 15(1):5689.
PMID: 38971796
PMC: 11227508.
DOI: 10.1038/s41467-024-50021-9.
Radiation-based immunogenic vaccine combined with a macrophage "checkpoint inhibitor" for boosting innate and adaptive immunity against metastatic colon cancers.
Xu H, Qin X, Guo Y, Zhao S, Feng X, Zhang R
Acta Pharm Sin B. 2024; 14(5):2247-2262.
PMID: 38799631
PMC: 11120279.
DOI: 10.1016/j.apsb.2024.02.015.
Hyperosmotic cold shock mouse melanoma cells encapsulated with doxorubicin for targeted treatment of melanoma.
Kong W, Wang C, Wang H, Liu H, Mu J, Jiang J
Front Oncol. 2024; 14:1403719.
PMID: 38751816
PMC: 11094257.
DOI: 10.3389/fonc.2024.1403719.
Cryo-shocked tumor cells deliver CRISPR-Cas9 for lung cancer regression by synthetic lethality.
Liu F, Xin M, Feng H, Zhang W, Liao Z, Sheng T
Sci Adv. 2024; 10(13):eadk8264.
PMID: 38552011
PMC: 10980270.
DOI: 10.1126/sciadv.adk8264.
Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy.
Liu M, Feng Y, Lu Y, Huang R, Zhang Y, Zhao Y
Sci Adv. 2024; 10(11):eadk2444.
PMID: 38478602
PMC: 10936870.
DOI: 10.1126/sciadv.adk2444.
Autologous cryo-shocked neutrophils enable targeted therapy of sepsis via broad-spectrum neutralization of pro-inflammatory cytokines and endotoxins.
Gao Q, Yan Y, Zhang J, Li X, Wang J, Feng Y
Front Chem. 2024; 12:1359946.
PMID: 38449477
PMC: 10914999.
DOI: 10.3389/fchem.2024.1359946.
Photo-Driven In Situ Solidification of Whole Cells through Inhibition of Trogocytosis for Immunotherapy.
Liu H, Huang K, Zhang H, Liu X, Jiang H, Wang X
Research (Wash D C). 2024; 7:0318.
PMID: 38384327
PMC: 10879965.
DOI: 10.34133/research.0318.
Targeted demethylation and activation of augment cancer immunogenicity through MHC class I.
Sun X, Watanabe T, Oda Y, Shen W, Ahmad A, Ouda R
Proc Natl Acad Sci U S A. 2024; 121(6):e2310821121.
PMID: 38300873
PMC: 10861931.
DOI: 10.1073/pnas.2310821121.